On Mar. 15, 2021, Altimmune announced additional preclinical data for its single dose intranasal COVID-19 vaccine candidate, AdCOVID. The preclinical studies were conducted at Altimmuneﾒs collaborating institutions, the University of Alabama at Birmingham (UAB) and Saint Louis University.

Based on data from Altimmuneﾒs other intranasal platform vaccine candidates, AdCOVID was expected to have extended stability at room temperature that would allow for cold chain-free shipment of the vaccine.